Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InflaRx N.V. - Common Stock (NQ:IFRX)

0.8750 -0.0019 (-0.22%)
Streaming Delayed Price Updated: 3:19 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InflaRx N.V. - Common Stock

< Previous 1 2 3 4 5 Next >
Nasdaq Tumbles 200 Points; McDonald's Posts Upbeat Q2 Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Tuesday. 
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
InflaRx's Stock Gains Following FDA Fast Track Status To Skin Disease Drug
The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG). 
Via Benzinga
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19
 
Via Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
LiveOne And 24 Stocks Moving Premarket
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 92.9% to $0.2295 in pre-market trading. Allena Pharmaceuticals said it previously entered into at market issuance sales agreement with B. Riley... 
Via Benzinga
Read Why Did Raymond James Slash Price Target On Inflarx
 
Via Benzinga
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Analyst Ratings for InflaRx
Analysts have provided the following ratings for InflaRx (NASDAQ:IFRX) within the last quarter: 
Via Benzinga
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! 
Via InvestorPlace
Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session
Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Recap: InflaRx Q4 Earnings
InflaRx (NASDAQ:IFRX) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease
InflaRx N.V. (NASDAQ: IFRX) has  
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Epizyme + 20 Stocks Moving In Monday's Pre-Market Session
Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday. 
Via Benzinga
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation... 
Via Benzinga
Recap: InflaRx Q1 Earnings
InflaRx (NASDAQ:IFRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings InflaRx missed estimated earnings by... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 71% to $11.57 after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading. 
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition
InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small... 
Via Benzinga
InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). ... 
Via Benzinga
70 Biggest Movers From Friday
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.